Last reviewed · How we verify
Dendritic cell immunotherapy
Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells.
Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells. Used for Cancer (specific indication not publicly detailed for this investigational product).
At a glance
| Generic name | Dendritic cell immunotherapy |
|---|---|
| Also known as | Immunotherapy Nusantara, Dendritic Cell vaccine, DCVax-L, DCVax, DCVax-Brain |
| Sponsor | PT. JES Kasih Nusantara Sejahterah |
| Drug class | Dendritic cell vaccine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Dendritic cells are harvested from the patient, cultured ex vivo, and loaded with tumor-associated antigens or engineered to express tumor antigens. These activated dendritic cells are then reinfused to prime and expand tumor-specific CD8+ T cells and CD4+ helper T cells, generating a durable anti-tumor immune response. This approach harnesses the body's adaptive immune system to recognize and eliminate malignant cells.
Approved indications
- Cancer (specific indication not publicly detailed for this investigational product)
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Flu-like symptoms
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1, PHASE2)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) (PHASE2)
- PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PHASE1)
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (PHASE2)
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (PHASE1)
- IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dendritic cell immunotherapy CI brief — competitive landscape report
- Dendritic cell immunotherapy updates RSS · CI watch RSS
- PT. JES Kasih Nusantara Sejahterah portfolio CI